Table 2.
Response rates to second- and third-generation TKIs of patients intolerant to previous treatment or with relapsed disease
| N | Res/intol | CHR (%) | MCyR (%) | CCyR (%) | Follow-up | |
|---|---|---|---|---|---|---|
| Dasatinib [23] | 186 | 127/59 | 90 | 52 | 39 | 8 months |
| Nilotinib [26] | 137 | 92/45 | 74 | 48 | 31 | 6 months |
| Bosutinib [29] | 288 | 200/88 | 86 | 53 | 41 | 24 weeks |
| Ponatinib [30] | 267 | 214/40a | N/A | 56 | 46 | 12 months |
Res imatinib-resistant, intol imatinib-intolerant, CHR complete hematologic response, MCyR major cytogenetic response, CCR complete cytogenetic response
aResistant to nilotinib or dasatinib